According to McKibben, a lower court held that Facebook violated Leader’s patent on 11 of 11 claims, but then invalidated Leader’s patent by finding that Leader had tried to sell its technology too soon (“on-sale bar,” in legal parlance.)

“Leader asked the Federal Circuit to overrule this verdict, because the company’s patent interests were protected by a ‘no-reliance’ agreement that negated any possibility of making offers before we had signed contracts,” said McKibben. “But the court ignored these agreements, accepted Facebook-doctored evidence, and misquoted my testimony to justify their decision.”

“We are extremely disappointed,” McKibben added. “The appeals process is supposed to correct legal errors by juries, not simply root around for new evidence to justify not overturning a jury that was fooled by Facebook tricks.”

McKibben may appeal to the U.S. Supreme Court. “We firmly believe that the jury erred in their one finding against Leader,” he says. “Facebook is using our invention, as the jury agreed, without our permission. This court just condoned hacking of intellectual property and fabrication of evidence as acceptable business practices.”

The case is Leader Technologies Inc. v. Facebook Inc., 2011-1366, U.S. Court of Appeals for the Federal Circuit (Washington). The lower court case is Leader Technologies Inc. v. Facebook Inc., 08-cv-862, U.S. District Court, District of Delaware (Wilmington).

More information about Leader: http://www.leader.com .

News Source: Leader Technologies Incorporated :: This press release was issued on behalf of the news source by Send2Press® Newswire, a service of Neotrope®. View all current news at: http://Send2PressNewswire.com .

This includes Microsoft’s Internet Explorer, Mozilla’s Firefox, Apple’s Safari, and Google’s Chrome on Windows-based desktop and laptop PCs in addition to Macintosh-based desktops and laptops. Further, WebPAX® enables users of mobile devices to access medical images through standard browsers on Apple’s iPad and iPhone, as well as all Google Android tablets and cell phones.

Without “zero-footprint” technologies, medical images can only be viewed by installing proprietary software that is different for each web browser, each operating system, and each hardware device.

U.S. Patent Number 8166381 issued on April 24, 2012. Heart IT’s “zero footprint” intellectual property portfolio also includes five previously-issued U.S. Patents: 6934698, 7457656, 7668835, 7958100, and 8055636. HeartIT’s intellectual property coverage for its issued patents extends through the year 2025. Additional related patents are pending review by the U.S. Patent and Trademark Office.

About Heart IT:
Founded in 2000 and headquartered near North Carolina’s Research Triangle Park, Heart IT is a global leader in the medical image web enablement field. Their flagship product, WebPAX®, was the world’s first FDA approved zero foot-print medical image workstation. It provides web-based medical image management technology and services to health care systems, large hospitals and private clinics as well as drug and device companies sponsoring multi-center clinical trials. Worldwide, WebPAX® systems currently provide secure web browser access to over one billion medical images. For more information visit our website at http://www.heartit.com .

“WebPAX” is a registered trademark of Heart Imaging Technologies, LLC. All other trademarks acknowledged.

News Source: Heart Imaging Technologies :: This press release was issued on behalf of the news source by Send2Press® Newswire, a service of Neotrope®. View all current news at: http://Send2PressNewswire.com .

Masterseek is the world’s largest B2B search engine, with over 100 million businesses in its database. The site offers users the ability to do a focused search for businesses in their area and abroad without the “clutter” associated with consumer-based search engines like Google. It also provides businesses opportunity to increase web presence with a searchable profile easily found online by their potential clients or potential business partners.

The search browser plug-in performs searches based on geo-location and allows direct search functions through three popular browsers. Upon entering a keyword into the internet browser application the search process is initiated. The server receives the request and searches Masterseek’s database for only relevant businesses given the criteria specified, returning the geo-specific results. Creators of the plug-in claim this search technology is more comprehensive, including businesses which other searches may discount while ensuring a higher level of relevance, eliminating those businesses more accurately which do not fit the proper criteria of the search.

“The technology is a step above pretty much any search engine’s ability to properly sort results we’ve ran across, and we are always researching what other search engines are doing right and what they are doing wrong,” said Rasmus Refer, CEO of Masterseek.com. “This is going to make searching for the right business on the user side a whole lot easier and much more accurate. Imagine if you are a business on one of the other popular search engines; how many business partners or potential clients are missing your site just because the search function is not as accurate as ours?”

Refer adds: “That we are continuing to make these kinds of drastic improvements to Masterseek.com, even though we are already the top B2B search engine, really shows our commitment to users and to the businesses that make a profile within our database. I hope we will continue to see more success because of innovations like this-and I hope the businesses that join our database become more successful as well.”

About Masterseek Corporation:
Masterseek is a B2B search engine and the largest business database in the world, with over 101 million businesses listed from all around the world. Businesses can create a profile on Masterseek.com free of charge and have full control over their business page. The web address is www.masterseek.com .

News Source: Masterseek Corporation :: This press release was issued on behalf of the news source by Send2Press® Newswire, a service of Neotrope®. View all current news at: http://Send2PressNewswire.com .

The United States District Court for the Northern District of California has ordered that Suprema distributors and OEM partners RBH Access Technologies, Inc. and RBH USA, Inc. are permanently prohibited from importing, offering for sale, distributing or selling within the United States products that incorporate non-licensed Suprema fingerprint sensors, including RBH-BFR-200-S, RBH-BFR-200-M, RBH-BFR-300-S, RBH-BFR-300-M, and RBH-BFR-USB.

SecuGen has alleged that optical fingerprint sensors made by Suprema Inc. and incorporated into biometric security products by Suprema and its distributors and OEM partners willfully infringe SecuGen’s patent, U.S. Patent No. 6,324,020, issued in 2001. This patent covers core imaging technology that SecuGen has developed to produce optical fingerprint sensors that are used in biometric security applications, such as door locks, time & attendance, access control, and labor tracking systems.

Suprema’s products accused of infringing SecuGen’s patent cover a wide range of optical fingerprint biometric Access Control, Time Attendance, Embedded Module, and PC Solution products, which include but are not limited to: BioEntry Plus, BioLite Net, BioLite Solo, BioMini, BioMini Plus, BioStation, BioStation T2, D-Station, SFM 2020-OP, SFM3020-OP, SFM3030-OD, SFM3040-OC, SFM3520-OP, SFM3530-OD, SFM4020-OP, SFR300-S, SFU300, and SFU500.

Since 1998, SecuGen has made considerable investment in research and development for its core technologies and to develop, maintain, and protect its valuable patents throughout the world including the U.S., Canada, Europe, and Asia. SecuGen’s patents have been tested through previous patent litigation with two separate companies, have been submitted for reexamination before the United States Patent and Trademark Office, and have survived and been strengthened by numerous invalidation attempts.

About SecuGen:
SecuGen Corporation (www.secugen.com) is the world’s leading provider of advanced, optical fingerprint recognition technology, products, tools and platforms for physical and information security. SecuGen designs and develops FBI-certified fingerprint readers and OEM components, developer kits and software, including NIST/MINEX-compliant algorithms. Known for high quality, ruggedness, and performance in a wide variety of applications and environmental conditions, SecuGen products are used by world-leading financial, medical, government, educational and corporate institutions and are sold through a partner network of over 200 original equipment manufacturers, independent software vendors and system integrators around the world.

SecuGen® is a registered trademark of SecuGen Corp. in the United States and other countries.

News Source: SecuGen Corporation :: This press release was issued on behalf of the news source by Send2Press® Newswire, a service of Neotrope®. View all current news at: http://Send2PressNewswire.com .

The patent-in-suit was issued in 2001 and covers core imaging technology for optical fingerprint sensors that are used in biometric security applications, such as door locks, time & attendance, access control, and labor tracking systems.

Products produced by Suprema and its OEM partners that are accused of infringing SecuGen’s patent include but are not limited to: BioEntry Plus, BioLite Net, BioLite Solo, BioMini, BioMini Plus, BioStation, BioStation T2, D-Station, SFM 2020-OP, SFM3020-OP, SFM3030-OD, SFM3040-OC, SFM3520-OP, SFM3530-OD, SFM4020-OP, SFR300-S, SFU300, SFU500, RBH-BFR-200-S, RBH-BFR-200-M, RBH-BFR-300-S, RBH-BFR-300-M, and RBH-BFR-USB.

Since 1998, SecuGen has made considerable investment in research and development for its core technologies and to develop, maintain, and protect its valuable patents throughout the world including the U.S., Canada, Europe, and Asia. SecuGen’s patents have been tested through previous patent litigation with two separate companies, have been submitted for reexamination before the United States Patent and Trademark Office, and have survived and been strengthened by numerous invalidation attempts.

About SecuGen:
SecuGen Corporation (www.secugen.com) is the world’s leading provider of advanced, optical fingerprint recognition technology, products, tools and platforms for physical and information security. SecuGen designs and develops FBI-certified fingerprint readers and OEM components, developer kits and software, including NIST/MINEX-compliant algorithms. Known for high quality, ruggedness, and performance in a wide variety of applications and environmental conditions, SecuGen products are used by world-leading financial, medical, government, educational and corporate institutions and are sold through a partner network of over 200 original equipment manufacturers, independent software vendors and system integrators around the world.

SecuGen® is a registered trademark of SecuGen Corp. in the United States and other countries.

News Source: SecuGen Corporation :: This press release was issued on behalf of the news source by Send2Press® Newswire, a service of Neotrope®. View all current news at: http://Send2PressNewswire.com .

At trial, Facebook was judged to be “literally infringing” Leader’s U.S. Patent No. 7,139,761 on 11 of 11 claims, and the jury also found that the invention was not obvious over the published prior art. Put simply, this means that the software engine driving Facebook is Leader’s invention.

However, the jury found the patent invalid on the theory that Leader had engaged in premature commercial activity more than one year before the patent application was filed. According to Leader, while much evidence was presented on both sides regarding infringement and prior art, Facebook presented no evidence to support its allegations of early commercial activity. Facebook had the “heavy burden” to present “clear and convincing evidence” to prove its allegation that Leader disclosed the invention prematurely. The clear and convincing standard was recently reaffirmed by the Supreme Court in Microsoft v. i4i.

Leader argues that an attempt to invalidate computer software inventions requires hard evidence like source code, engineering documents, developer testimony, drawings, schematics and expert witnesses to prove early commercial activity. Facebook provided no such proof. Leader cites cases where invalidity verdicts were overturned when infringers failed to provide hard evidence.

The law on Facebook’s burden of proof requires Facebook to prove that each and every element of Leader’s invention was present in the alleged 2002 offers. Leader states that various products were sold in 2002, but none of them included the invention “because it did not exist at that time.”

Leader argues that Facebook had all versions of Leader’s source code and engineering documents, and that Facebook would surely have used the code had it actually discovered any evidence of Leader’s alleged early commercial activity. CEO Mike McKibben said, “Facebook didn’t produce any of our source code because the programmer notations in our code prove they are wrong.”

Leader argues that “if requiring clear and convincing evidence of invalidity is to be more than an empty semantic exercise, it must mean that the jury’s verdict here cannot stand.”

Facebook’s response is due according to the court Rules.

About Leader:
Leader Technologies Incorporated is located in Columbus, Ohio and may be reached thru John Needham at 614-890-1986 or online at www.leader.com .

- RSS news feed for Leader: http://send2pressnewswire.com/author/leader-technologies-incorporated/feed .

News Source: Leader Technologies Incorporated :: This press release was issued on behalf of the news source by Send2Press® Newswire, a service of Neotrope®. View all current news at: http://Send2PressNewswire.com .

The patent is U.S. 5,723,391 and covers the manufacture of Silicon Carbide, or Moissanite, gemstones. The filing requests the USPTO review and consider the validity of this U.S. patent in light of three “prior art” publications provided to the USPTO by BetterThanDiamond. The three publications span three decades – one each from the 60′s, 70′s and 80′s. Per 35 USC 103, a patent may not be granted when the subject matter as a whole would have been obvious at the time the invention was made in light of prior art. None of the three provided publications, or “prior art,” had been disclosed to the patent examiner or USPTO at the time the current patent was granted.

“The patent system is designed to promote and protect innovation,” said Less P. Wright, President, BetterThanDiamond.com. “This patent however, was thrown out in Korea on the basis of ‘lack of innovation’ – and we couldn’t agree more. Our filing, however, goes beyond opinions regarding innovation or lack thereof, and provides three prior art publications that make obvious to those skilled in the art how to manufacture silicon carbide, or Moissanite, gemstones. We do not believe Charles & Colvard’s patent would have been granted had the USPTO been aware of these previous publications. Thus, we are filing today to allow the USPTO to review the patent’s validity in light of these new disclosures.”

BetterThanDiamond has had several breakthroughs related to the manufacture and improved optical properties of Silicon Carbide or Moissanite, for its “Mira Moissanite” program. However, they have been prevented from combining all of their breakthroughs into a single product offering due to the current patent held by Charles & Colvard. These breakthroughs include patent applications in progress for a new Hearts and Arrows round cut, and the ability to atomically enhance the colorlessness of all Moissanite, including the Moissanite sold by Charles & Colvard. For example – the Mira enhancement process is able to take a typical 1.5ct round from Charles & Colvard, which grades K or “Faint Color” on the diamond color scale, and permanently transform it to H color, or true near colorless. H color grade is a whiter diamond color much more in demand by jewelry consumers than K, or “faint color,” and BetterThanDiamond intends to greatly expand its production of Mira Moissanite once the patent issue is resolved.

The patent re-exam process is expected to take between 3 to 6 months before the USPTO issues a decision.

“We anticipate that our current filing will result in the invalidation of the current patent held by Charles & Colvard. With a successful outcome and our manufacturing no longer restricted, we expect to further surprise jewelry lovers globally with the true beauty of our Mira Moissanite. At that point, we can utilize all of our technology and show Mira’s ‘Beauty Beyond Diamond™’ properties to full effect,” said Mr. Wright.

About BetterThanDiamond:
With its background in solid state chemistry and materials science, BetterThanDiamond.com is focused on the research, development and delivery of the world’s most stunning lab grown gems. A 17 year old private company with customers in over 25 countries, BetterThanDiamond supplies lab grown jewelry products to jewelers and consumers globally.

For more information, visit: http://BetterThanDiamond.com .

All trademarks acknowledged.

News Source: BetterThanDiamond, Inc. :: This press release was issued on behalf of the news source by Send2Press® Newswire, a service of Neotrope®. View all current news at: http://Send2PressNewswire.com .

The complaint is related to U.S. Patent No. 6,324,020 issued in 2001 and owned by SecuGen, which covers invaluable technology for acquiring high quality fingerprint images that are crucial to the performance and accuracy of optical fingerprint sensors in biometric security applications.

Suprema’s products accused of infringing SecuGen’s patent cover a vast range of optical fingerprint biometric Access Control, Time Attendance, Embedded Module, and PC Solution products, which include but are not limited to: BioEntry Plus, BioLite Net, BioLite Solo, BioMini, BioMini Plus, BioStation, BioStation T2, D-Station, SFM 2020-OP, SFM3020-OP, SFM3030-OD, SFM3040-OC, SFM3520-OP, SFM3530-OD, SFM4020-OP, SFU300, and SFU500.

Since 1998, SecuGen has made considerable investments to conduct true research and development on its core technologies and to develop, maintain, and protect its valuable patents throughout the world in North America, Europe, and Asia.

“We have always respected the proprietary rights of others and expect our competitors to do the same,” stated Won Lee, President and CEO of SecuGen. “We will vigorously defend our intellectual property rights including our long-standing patents.”

In addition to seeking a declaration by the Court that Suprema’s importation, use, sale or offer to sell fingerprint biometric products in the United States infringe SecuGen’s patent, SecuGen is seeking preliminary and permanent injunctions against Suprema’s future infringement of the patent and recovery of treble damages for knowing and willful infringement by Suprema.

About SecuGen:
SecuGen Corporation (www.secugen.com) is the world’s leading provider of advanced, optical fingerprint recognition technology, products, tools and platforms for physical and information security. SecuGen designs and develops FBI-certified fingerprint readers and OEM components, developer kits and software, including NIST/MINEX-compliant algorithms. Known for high quality, ruggedness, and performance in a wide variety of applications and environmental conditions, SecuGen products are used by world-leading financial, medical, government, educational and corporate institutions and are sold through a partner network of over 200 original equipment manufacturers, independent software vendors and system integrators around the world.

SecuGen Corporation, 2065 Martin Avenue Suite 108, Santa Clara, Calif. 95050, USA; Tel 408.727.7787.

- RSS news feed for SecuGen Corporation: http://send2pressnewswire.com/author/secugen-corporation/feed .

News Source: SecuGen Corporation :: This press release was issued on behalf of the news source by Send2Press® Newswire, a service of Neotrope®. View all current news at: http://Send2PressNewswire.com .

The Company holds three additional U.S. patents and five patent applications pending, all of which underlie the Company’s WebPAX® Medical Image Management Systems, a commercialized and FDA-approved technology that enables viewing and analysis of diagnostic-quality medical images in a bare-bones web browser with full PACS capabilities and that seamlessly integrates into EMRs, EHRs and web-portals.

The parent application was filed in 2000. Before allowing the patent USPTO examiners considered thousands of related patents, journal articles, and other publications dating back to 1987, of which 114 were specifically cited. No prior art was found that described how web browser redirection could be used to manage medical images across different hospitals.

“When we filed this patent everyone was focused on using desktop applications for viewing medical images within a single hospital. We were the first to describe how to design a system that provides global access to a distributed database of medical images by leveraging the now-ubiquitous World Wide Web framework,” said co-founder Robert M. Judd, Ph.D.

The cloud computing revolution is poised to have a major impact on the healthcare IT market, with the most profound disruptive influence in medical imaging, a $170 billion a year market. Despite the DICOM standard, the medical imaging industry is replete with technical fragmentation, inoperability dysfunction and sharing inefficiencies. Consequently, an estimated $30 billion in the U.S. is spent on unnecessary medical imaging, about $15 billion of which is due to redundant procedures that result from a physician’s lack of access to prior imaging exams. The Company’s WebPAX® technology allows the efficient sharing, viewing and analysis of medical images from any DICOM source (modality or PACS), eliminating the time and cost associated with redundant exams, avoiding excessive radiation exposure for patients and obviating the costs and inefficiencies of shuttling around and managing CDs.

“Customer demand from hospitals, imaging centers, physician practices, payors and ACOs, combined with the availability of Web 2.0 and cloud computing technologies, will make the days of traditional PACS, one-off viewers and extensive infrastructure associated with image management numbered,” said Dr. Judd.

The electronic medical record is intended to serve as the sole integration point of all types of medical data in order to provide a cohesive and comprehensive view of the patient. However, despite the critical importance of medical images to the entire longitudinal medical record, integration of images into the EMR has proved elusive for a variety of technical, territorial, cost and work-flow considerations.

As a PACS-vendor neutral and web-based architecture, the WebPAX® platform complements and maximizes the utility of any existing PACS and EMR/EHR investments by providing zero-footprint access to all medical images and videos through a simple web-link (URL) within a third-party EMR/EHR system that automatically points to the images associated with the specific patient imaging procedure which can be viewed with diagnostic quality from any web-connected computer or device.

“Whether access to images are made available through the EMR, EHR, web portals, PACS-interface and/or cloud-based delivery models, the difficulty lies in providing immediate web-access to images stored in different hospitals or data centers as images accumulate,” stated Dr. Judd. “Traditional approaches have required that images are copied from one hospital to another before they can be viewed, which is intrinsically slow, cumbersome and expensive. Our proprietary technology provides that functionality with a single mouse click and this method, which is covered by this newly issued patent, is the most efficient technical approach possible within the framework of World Wide Web technologies.”

“This patent places the Company in a unique position and provides protection of our core technology as the scaling of medical images across enterprises and/or within the cloud continues to accelerate. This advancement is important because our patented technology eliminates the need to copy images from one hospital to another by automatically routing the physician’s web browser to the hospital where the image is actually stored. As a result, physicians have immediate access to images located at different hospitals or data centers.”

As medical imaging moves to the cloud, this patented technology also covers the ability to efficiently provide web browser access to medical images stored in multiple geographic locations, which has important implications for cloud-based and SaaS providers. “Using a single data center to store all images from all hospitals or imaging providers – within a network – is impractical due to the enormous size of medical images. WebPAX’s patented technology enables cloud-based providers to utilize multiple, geographically-dispersed data centers while acting as a single information source from the physician’s perspective. Our newly issued patent protects the use of web browser redirection in this context of seamless controlled web access routing to medical images stored in different geographic locations.”

Founded in 2000 and headquartered near North Carolina’s Research Triangle Park, WebPAX provides zero-footprint, web-based medical image management technology and services to health care systems, large hospitals and private clinics as well as drug and device companies sponsoring multi-center clinical trials. Worldwide, WebPAX® systems currently provide secure web browser access to over 500 million medical images.

For more information, visit: http://www.heartit.com .

News Source: Heart Imaging Technologies :: This press release was issued on behalf of the news source by Send2Press® Newswire, a service of Neotrope®. View all current news at: http://Send2PressNewswire.com .

“We believe this is an important moment for Sample Digital because the ’416 Patent covers both current and future technology relating to the collaboration of media content throughout the entire pre- and post-production process,” stated Patrick Macdonald King, CEO of Sample Digital.

“The patent is a culmination of extensive research, creative vision and real-world application of Sample’s technology and allows studios, broadcast and cable companies to easily and effectively collaborate on all aspects workflow and production of media content. Sample Digital believes the ’416 patent provides a competitive edge to Sample Digital and further marks Sample Digital as the leader in this field.”

About Sample Digital Holdings LLC
Hollywood-based Sample Digital (www.sampledigital.com) delivers targeted workflow and media asset management applications and services to companies who produce, distribute and license audio-visual and rich media content.

Sample Digital’s suite of applications, including dax|D3™, Digital Dailies® and iDailies®, optimize business process in content production and distribution management for such creative leaders as 20th Century Fox, CBS, Warner Bros., Showtime, Lifetime Television, Summit Entertainment, and Lionsgate. Our clients have found using Sample Digital’s platform reduces production and distribution expenditures, improves time to market and minimizes risk – both creatively and financially.

Sample Digital’s core platform, dax|D3, is a highly secure web-based environment where users can share ideas, information and content created throughout the production or campaign lifecycle, or as required for trafficking and distribution of final product. dax|D3 incorporates media production workflow and collaboration, transcoding, distribution and security services into one robust, extendible solution available via desktop, set top box and mobile applications such as dax|Mobile, an iPad application available in April 2011.

News Source: Sample Digital :: This press release was issued on behalf of the news source by Send2Press® Newswire, a service of Neotrope®. View all current news at: http://Send2PressNewswire.com .

Plain text copy of press release: send2pressnewswire.com/mediadrome/2011-02-0201-005.txt .
PDF copy of release: send2pressnewswire.com/mediadrome/news_2011-02-0201-005.pdf .